Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9603796 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9205048 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
US11369566 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
US9233068 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders |
Dec, 2029
(6 years from now) | |
US8318817 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2030
(6 years from now) | |
US9220796 | ALK ABELLO | Sterilization of ciprofloxacin composition |
Jul, 2035
(11 years from now) | |
US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(14 years from now) | |
US11246863 | ALK ABELLO | Ciprofloxacin otic composition and kits and method for using same |
Nov, 2038
(15 years from now) |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; Treatment of otic infection or inflammation; The treatment of acute otitis externa in patients 6...
Dosage: INJECTABLE, SUSPENSION;OTIC
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic